Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 61,680

Document Document Title
WO/2018/190325A1
A compound represented by formula (1), or a salt thereof, is provided that is effective as a wood preservative. In the formula, R1 represents an optionally substituted C1-C6 alkyl group, a C1-C6 haloalkyl group, etc., R2 represents a hal...  
WO/2018/188590A1
Fluorine-substituted indazole compounds, pharmaceutical compositions containing these compounds and uses thereof. The compounds and pharmaceutical compositions can be used as soluble guanylate cyclase simulators.  
WO/2018/190352A1
A novel compound is provided which controls plant disease. This pyridone compound is novel and can control plant disease.  
WO/2018/191160A1
The present invention describes the use of a NK1-antagonist, in combination with 6- propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to facilitate the treatment of a patient suffering from a synucleinopathy by enabling a therape...  
WO/2018/189479A1
The present invention relates to conjugated polymers supporting chemical probes and the use thereof for the preparation of chemical sensors based on carbon nanotubes allowing the selective detection of analytes in the water.  
WO/2018/191283A1
Described herein are glucocorticoid receptor modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer and hypercortisolism.  
WO/2018/190349A1
A novel compound is provided which controls plant disease. This pyridone compound is novel and can control plant disease.  
WO/2018/191171A1
Provided herein, inter alia, are methods of treating cancer or cutaneous T-cell lymphoma (CTCL) using compounds of the invention.  
WO/2018/189356A1
The invention relates to an organic compound, in particular for the application in optoelect devices. According to the invention, the organic compound comprises or consists of - a first chemical moiety with a structure of formula (I) and...  
WO/2018/189695A1
The present invention relates to novel crystalline forms of Neratinib and processes for preparation thereof. Neratinib is a tyrosine kinase inhibitor formula (I), having the chemical name (2E)-N-[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phe...  
WO/2018/189340A1
The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (...  
WO/2018/190324A1
An antifungal agent with excellent antifungal activity is provided. An antifungal agent is provided which contains the pyridone compound represented by formula (1), or a salt thereof, as an active component. In the formula, R1 represents...  
WO/2018/190522A1
The present invention provides a novel compound and an organic light emitting device comprising the same, the novel compound including a substituted or unsubstituted biphenyl fluorenyl group as a core structure, wherein any one benzene r...  
WO/2018/187503A1
Methods of improving neurodegenerative disease with CCR3 modulating agents are provided. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in ...  
WO/2018/184882A1
The present invention relates to compounds of formula (I), wherein the variables are defined as given in the description and claims. The invention further relates to uses and composition for compounds of formula (I).  
WO/2018/187294A1
The present application provides novel pyrimido-pyridazinone compound combinations and methods for preparing and using these combinations. These compounds are useful in treating cancer or tumor growth or metastasis in patients by adminis...  
WO/2018/187187A1
A deuterated compound having the structure of Formula I: or a pharmaceutically acceptable salt, solvate, or prodrug thereof; or a salt of a prodrug thereof; or a hydrate or polymorph thereof; wherein Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y...  
WO/2018/184115A1
Compounds comprising quinazolinone derivatives and methods of identification and use of imaging agents. The compounds have the general formula I: wherein R2 is selected from halogen, halosubstituted alkyl, alkyl, hydroxyl-alkyl, and amin...  
WO/2018/187652A1
The present invention relates to 2,4-diaminopyrimidines of formula (I) and pharmaceutically acceptable salts thereof, purification methods for the same, pharmaceutical compositions containing them, methods of obtaining and using them for...  
WO/2018/186365A1
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...  
WO/2018/185675A1
The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4, L and m are as defined herein, which are active as modulators of retinoid-related orphan recept...  
WO/2018/183857A1
The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in th...  
WO/2018/177981A1
The invention relates to aromatic compounds which are suitable for synthesizing asymmetrical polydentate ligands. The invention further relates to a method for synthesizing asymmetrical polydentate ligands and metal complexes comprising ...  
WO/2018/182051A1
The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for- diseases such as cardiac failure, diabetes and the like. A compound repr...  
WO/2018/184019A1
The present invention presents 2-(acylamino)imidazoles with therapeutic activity, including selective activity against cancer cells, and compositions comprising them. Methods of using and preparing the 2-(acylamino)imidazoles are also pr...  
WO/2018/183960A1
Compounds useful as contrast agents in image-guided surgery are provided. The compounds comprise a latent cationic lysosomotropic fragment that is detectable upon cleavage by lysosomal proteases within treated tissues, particularly withi...  
WO/2018/178679A1
The invention provides a combination comprising: (i) a compound of formula (Io) : (Io) or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims; and (ii) a co...  
WO/2018/178384A1
The invention relates to a compound of formula (I): A-B-D-E (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein: A is selected from monocyclic and bicyclic h...  
WO/2018/183122A1
Described herein are ASK1 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders ass...  
WO/2018/181345A1
Provided is a compound which has an Nrf2-activating activity and is expected to be useful as a prophylactic or therapeutic agent for diseases associated with oxidative stress, particularly hepatitis (e.g., non-alcoholic steatohepatitis (...  
WO/2018/178039A1
The present invention relates to crystalline forms of ethyl[3-[2-chloro-4-fluoro-5-(1- methyl-6-trifluoromethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimid in-3-yl)phenoxy]-2-pyridyl- oxy]acetate (CAS 353292-31-6), herein after also referred to ...  
WO/2018/181860A1
The present invention addresses the problem of providing a compound used for treatment or prevention of peripheral neuropathies. Provided is a therapeutic or prophylactic agent for peripheral neuropathies, the agent containing, as an act...  
WO/2018/181847A1
The purpose of the present invention is to provide a novel aromatic compound capable of having GPR40 agonistic activity and activity in accelerating GLP-1 secretion. A compound represented by formula (I) (wherein the symbols are as defin...  
WO/2018/177899A1
The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of...  
WO/2018/183795A1
The present application relates to methods of preparing a compound of formula I: (I), or a pharmaceutically acceptable salt or solvate thereof.  
WO/2018/183171A1
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...  
WO/2018/178280A1
The present invent ion relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present inv ention are useful as pI3Κβ...  
WO/2018/183145A1
Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for p...  
WO/2018/178277A1
The present invention is directed to novel natural product-derived combretastatin- based compounds useful as payloads in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in connectio...  
WO/2018/181456A1
Provided is a compound represented by the formula, or a salt thereof, the compound having RORγt-inhibiting activity and being useful as a prophylactic or therapeutic agent for autoimmune or allergic diseases.  
WO/2018/183964A1
Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1 -dependent disorders and enhancing an immune response. Also described are methods of inhibiting ...  
WO/2018/182050A1
Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I) : wherein each symbol is as described in the DESCRIPTION, or a salt thereof may...  
WO/2018/178938A1
The disclosures herein relate to novel compounds of formula (IA) wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associat...  
WO/2018/183349A1
The present invention relates to pharmaceutical capsule compositions comprising the compound niraparib as an active pharmaceutical ingredient, suitable for oral administration as well as to methods for their preparation. Also described h...  
WO/2018/183354A1
The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.  
WO/2018/181892A1
The purpose of the present invention is to provide a compound which has an anti-RNA virus activity and is useful as an anti-RNA virus drug, particularly an anti-influenza virus drug. The present invention provides a compound represented ...  
WO/2018/172852A1
The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and co...  
WO/2018/173882A1
Provided is a cyclic azine compound having exceptional heat resistance, a long service life in an organic electroluminescent element, and exceptional low-voltage drive properties or luminous efficiency. A cyclic azine compound having a s...  
WO/2018/170997A1
Provided is a method for preparing a compound represented by formula I by means of a compound represented by formula (II), wherein the definitions of each group are as described in the description. Said route has the characteristics of b...  
WO/2018/175449A1
The present invention relates to proline amide compounds and their azetidine derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition c...  

Matches 1 - 50 out of 61,680